We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2015 by Jianhua Chen, Hunan Province Tumor Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01549093
First Posted: March 8, 2012
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Jianhua Chen, Hunan Province Tumor Hospital
  Purpose
The purpose of this study is to determine whether Endostar with Gemcitabine-Carboplatin are more effective than Gemcitabine-Carboplatin alone in the treatment of Non-Small Cell Lung Cancer (NSCLC),and about Endostar ,Compared with intravenous, Continued vein-pumping maby is a more effective way.

Condition Intervention Phase
Non-small Cell Lung Cancer Drug: Gemcitabine,Carboplatin,Endostar Drug: Gemcitabine(G) Carboplatin(C) Endostar Drug: Gemcitabine(G) Carboplatin(C) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Controlled Study About Endostar Continued Pumping or Injecting Into Vein Combining With Gemcitabine-Carboplatin Versus Gemcitabine-Carboplatin Alone to Treat Non-Small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:


Further study details as provided by Jianhua Chen, Hunan Province Tumor Hospital:

Primary Outcome Measures:
  • Progression free survival (PFS) [ Time Frame: two years ]

Secondary Outcome Measures:
  • Overall survival (OS) [ Time Frame: two years ]
  • Clinical benefit rate (CBR) [ Time Frame: two years ]
  • The level change of CECs,VEGF,TSP-1,VEGFR,P1GF,MVD in blood. [ Time Frame: two years ]
  • adverse reaction [ Time Frame: two years ]
  • Time to progression(TTP) [ Time Frame: two years ]

Estimated Enrollment: 90
Study Start Date: August 2011
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Endostar -Continued Pumping into+GC
Endostar that is Continued Pumping into vein Combining With Gemcitabine -Carboplatin
Drug: Gemcitabine,Carboplatin,Endostar
Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
Active Comparator: Endostar -injecting into +GC
Endostar that is injecting into vein with Gemcitabine -Carboplatin
Drug: Gemcitabine(G) Carboplatin(C) Endostar
Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
Active Comparator: GC
Gemcitabine -Carboplatin
Drug: Gemcitabine(G) Carboplatin(C)
Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles

Detailed Description:

Endostar have anti-tumor activity by against vascular endothelial growth factor for initial treatment. This study was designed to evaluate the safety and efficacy of Endostar Continued vein-pumping Combining with Gemcitabine-Carboplatin (GC)chemotherapy in patients with NSCLC,and seeking for more effective injection.

Methods:

In this randomized, open label, 90 patients are planned to be enrolled at random into 3 arms(1:1:1): Experimental: Endostar -Continued Pumping into+Gemcitabine-Carboplatin(GC),Active Comparator: Endostar -injecting into +Gemcitabine-Carboplatin(GC),Active Comparator: Gemcitabine-Carboplatin(GC),

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically diagnosed NSCLC;
  2. primary treatment,inoperable stage III/IV NSCLC;
  3. Age of 18-70years; Gender Not Required;
  4. Adequate hematologic, renal, and hepatic function ,Specific index as follows:

    liver function: S-Bilirubin ≤1.5 ULN ; Transaminase≤2 ULN. renal function: S-Creatinine ≤1.2 ULN; blood urea nitrogen ≤1.2 ULN . ULN: upper normal limit. Marrow Hemopoietic Function: WBC≥4.0×10^9/l, ANC≥2.0×10^9/l platelet count ≥100×10^9/l, Hb≥100 g/l;

  5. ECOG PS 0-2,Life expectancy ≥ 3 months; endure more than two cycle chemotherapy;
  6. The patients have explicit lung tumor lesions and the lesions were measurable; (According to the standard of RECIST1.1, they should have at least one of accurately measurable lesions with the largest diameter ≥ 10mm by spiral CT, MRI);
  7. No history of serious drug allergy;
  8. Informed consent should be obtained before treatment.

Exclusion Criteria:

  1. Symptomatic brain metastases with cognitive disorder,bone metastases with complications;
  2. Major organ dysfunction and Serious Heart Disease( congestive heart-failure,incontrollable high-risk arrhythmia,unstable angina, valvular disease, myocardial infarct and Resistant hypertension,);
  3. Serious complications and investigator consider it is unsuited enrolling;
  4. Pregnant or lactating women;
  5. Allergic to research drug;
  6. participating in other experimental trials and receive the treatment in four weeks;
  7. The position that is for observing curative effect have a radiotherapy.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01549093


Contacts
Contact: Jianhua Chen, master 0086-731-89762221 cjh_1000@163.com

Locations
China, Hunan
HuNan province tumor hospital Recruiting
Changsha, Hunan, China, 410000
Contact: Jianhua Chen, master    0086-731-89762221    cjh_1000@163.com   
Principal Investigator: Jianhua Chen, master         
Sponsors and Collaborators
Hunan Province Tumor Hospital
Investigators
Principal Investigator: Jianhua Chen, master Hunan Province Tumor Hospital
  More Information

Responsible Party: Jianhua Chen, professer, Hunan Province Tumor Hospital
ClinicalTrials.gov Identifier: NCT01549093     History of Changes
Other Study ID Numbers: HunanPTH022
First Submitted: February 27, 2012
First Posted: March 8, 2012
Last Update Posted: October 12, 2017
Last Verified: March 2015

Keywords provided by Jianhua Chen, Hunan Province Tumor Hospital:
Non-small cell lung cancer
Endostar
Continued Pumping into
Gemcitabine
Carboplatin

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Gemcitabine
Carboplatin
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs